SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-23-035032
Filing Date
2023-12-21
Accepted
2023-12-21 07:58:05
Documents
16
Period of Report
2023-12-21
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K nby20231218_8k.htm   iXBRL 8-K 47221
2 EXHIBIT 4.1 ex_608120.htm EX-4.1 107838
3 EXHIBIT 10.1 ex_608121.htm EX-10.1 80151
8 pic1.jpg GRAPHIC 9157
  Complete submission text file 0001437749-23-035032.txt   428661

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA nby-20231221.xsd EX-101.SCH 3402
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nby-20231221_def.xml EX-101.DEF 11422
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE nby-20231221_lab.xml EX-101.LAB 15311
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nby-20231221_pre.xml EX-101.PRE 11582
10 EXTRACTED XBRL INSTANCE DOCUMENT nby20231218_8k_htm.xml XML 2565
Mailing Address 2000 POWELL STREET, SUITE 1150 EMERYVILLE CA 94608
Business Address 2000 POWELL STREET, SUITE 1150 EMERYVILLE CA 94608 (510) 899-8800
NovaBay Pharmaceuticals, Inc. (Filer) CIK: 0001389545 (see all company filings)

IRS No.: 680454536 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33678 | Film No.: 231502790
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)